We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




NIH Launches Center to Study Genomics and Health Disparities

By Biotechdaily staff writers
Posted on 11 Apr 2008
A new U.S. More...
center has been created that will focus on genomic research and the way populations are impacted by diseases, including obesity, diabetes, and hypertension.

The U.S. National Institutes of Health (NIH; Bethesda, MD, USA) announced the establishment of the NIH Intramural Center for Genomics and Health Disparities (NICGHD), which will employ a genomics approach, collecting and analyzing genetic, clinical, lifestyle and socio-economic data to study a range of clinical conditions that have perplexed and troubled public health experts for decades. The trans-NIH center will be directed by internationally renowned genetic epidemiologist Charles N. Rotimi, Ph.D., former director of the National Human Genome Center at Howard University (Washington DC, USA).

"This new center will be an NIH resource to help move research related to the complex factors underlying health disparities into the 21st century,” said NIH director Elias A. Zerhouni, M.D. "Synergy among the center's genetic and genomic researchers and disease experts in existing NIH research programs will advance our understanding of health disparities for the benefit of minority groups and all Americans.”

"The priority of our center will be to understand how we can use the tools of genomics to address some of the issues we see with health disparities,” Dr. Rotimi said. "The availability of tremendous expertise and the remarkable research infrastructure at NIH will make our research activities more robust and will allow us to tackle questions in ways that were not feasible in the past.”

Genomic research has determined that the genomes of any two individuals are very similar. However, the subtle genomic differences that remain contribute to unique biologic traits, such as hair and eye color, as well as to the susceptibility to diseases and individual responses to drugs. Additional factors contribute to health and disease, including diet, exercise routines, and access to medical care. Genetic epidemiologists study genetic differences in combination with environmental factors to assess disease susceptibility and resistance among individuals and population groups.

NICGHD will be established within the NIH Office of Intramural Research and administered by the National Human Genome Research Institute (NHGRI). Additional support for the center will come from the NIH Office of the Director, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Center for Information Technology. The research activities of NICGHD will take place on the NIH Bethesda campus.

Building upon his previous research, Dr. Rotimi will continue efforts to develop genetic epidemiology models and population-genetics research projects that provide insights about the interrelationships of culture, lifestyle, genetics, genomics, and health. His research explores patterns and determinants of common complex diseases that affect populations both living in Africa today and those that are part of the African diaspora.

Dr. Rotimi, who also has been appointed senior investigator in the Inherited Disease Research Branch in NHGRI's Division of Intramural Research, has been extensively involved in a number of genetic epidemiology projects that are being conducted in several African countries, China, and in the United States. Dr. Rotimi is the founding and current president of the African Society of Human Genetics, whose membership is interested in using genomic tools to impact health for African people and the global community.

An additional focus of NICGHD will be to provide training opportunities for students and established scientists from developing countries and from minority groups in the United States.


Related Links:
National Institutes of Health
NIH Intramural Center for Genomics and Health Disparities

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gastrointestinal Panel
Xpert® GI Panel
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.